Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Arecor Therapeutics's share price for the quarter that ended in Dec. 2025 was €0.785. Arecor Therapeutics's Shares Outstanding (EOP) for the quarter that ended in Dec. 2025 was 37.76 Mil. Therefore, Arecor Therapeutics's market cap for the quarter that ended in Dec. 2025 was €29.64 Mil.
Arecor Therapeutics's quarterly market cap
declined
from Dec. 2024 (€32.28 Mil) to Jun. 2025 (€23.22 Mil) but then
increased
from Jun. 2025 (€23.22 Mil) to Dec. 2025 (€29.64 Mil).
Arecor Therapeutics's annual market cap
declined
from Dec. 2023 (€63.09 Mil) to Dec. 2024 (€32.28 Mil) and
declined
from Dec. 2024 (€32.28 Mil) to Dec. 2025 (€29.64 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Arecor Therapeutics's Enterprise Value for Today is €19.86 Mil.
Arecor Therapeutics (FRA:6UI) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Arecor Therapeutics Market Cap Related Terms
Arecor Therapeutics Market Cap Historical Data
* Premium members only.
The historical data trend for Arecor Therapeutics's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:6UI vs VRTX, REGN, RVMD: Market Cap Comparison
For the Biotechnology subindustry, Arecor Therapeutics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Arecor Therapeutics Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Arecor Therapeutics's Market Cap distribution charts can be found below:
* The bar in red indicates where Arecor Therapeutics's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Arecor Therapeutics's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Arecor Therapeutics (FRA:6UI) has a Market Cap of €26.90 Mil as of Aug. 01, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Arecor Therapeutics and its competitors. According to the industry distribution chart, Arecor Therapeutics ranks #978 out of 1422 companies in the Biotechnology industry, placing it in the top 68.8%.
Is Arecor Therapeutics' Market Cap too high?
Arecor Therapeutics' current Market Cap is €26.90 Mil. Based on the distribution chart, Arecor Therapeutics ranks #978 out of 1422 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Arecor Therapeutics has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does Arecor Therapeutics' Market Cap compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Arecor Therapeutics ranks #978 out of 1422 companies for Market Cap. This places Arecor Therapeutics in the lower half of its industry. The industry median Market Cap is 109.62. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 109.62, based on 1,422 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Arecor Therapeutics and its competitors. For the Biotechnology industry, the median Market Cap is 109.62 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Arecor Therapeutics's current Market Cap is €26.90 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arecor Therapeutics stock overvalued right now?
Arecor Therapeutics (FRA:6UI) has a current Market Cap of €26.90 Mil. The stock's GF Value™ is €0.45, compared to a current price of €0.63 — trading 40% above its estimated fair value. The current Market Cap is €26.90 Mil. Arecor Therapeutics' overall GF Score™ is 37/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Arecor Therapeutics (FRA:6UI), the current Market Cap is €26.90 Mil as of Aug. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Arecor Therapeutics (FRA:6UI) Overvalued in 2026?
Based on GuruFocus' analysis, Arecor Therapeutics stock appears to be overvalued.
The current stock price of €0.63 is trading 40% above its estimated GF Value™ of €0.45.
Key valuation signals for FRA:6UI:
Market Cap: €26.90 Mil
GF Value™: €0.45 vs. price of €0.63 (40% above fair value)
No single metric tells the full story. See the FRA:6UI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Arecor Therapeutics PLC is a focused biopharmaceutical company. The company is transforming patient care by bringing medicines to market through the enhancement of existing therapeutic products. By applying an proprietary formulation technology platform, Aresta. It is developing a portfolio of proprietary products in diabetes and other indications and working with pharmaceutical and biotechnology companies to deliver enhanced reformulations of their therapies. Geographically, it operates in the UK, Europe (excl. UK) & Middle East, and the USA, out of which the majority is from the Europe (excl. UK) & Middle East.
37GF Score
Get the complete analysis for FRA:6UI
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:6UI has been successfully added to your 
